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169 Exercise and respiratory muscle function in patients with cystic
ﬁbrosis
T.G. Dassios1, A. Katelari2, S. Doudounakis2, G. Dimitriou3. 1Addenbrookes
Hospital, Cambridge University Hospitals NHS Trust, Neonatal Intensive Care
Unit, Cambridge, United Kingdom; 2“Aghia Sophia” Children’s Hospital,
Department of Cystic Fibrosis, Athens, Greece; 3University of Patras Medical
School, Department of Paediatrics, Patras, Greece
Exercise plays a well-established role in Cystic Fibrosis (CF) as exercise intol-
erance is strongly associated with clinical deterioration and disease progression.
Malnutrition and airway obstruction compromise respiratory muscle function in
CF patients and place affected patients in increased risk of respiratory muscle
fatigue and respiratory failure. Respiratory muscle function in CF can be assessed
by means of maximal expiratory pressure (Pemax), maximal inspiratory pressure
(Pimax) and pressure-time index of the respiratory muscle (PTImus). We assessed
nutrition, pulmonary function and respiratory muscle function in 37 CF patients
that undertook regular aerobic exercise and in a control group matched for age and
gender which consisted of 44 CF patients that did not undertake regular exercise.
Pimax and Pemax were signiﬁcantly higher in the exercise group compared to the
control group (p< 0.001 and p< 0.001 respectively) while PTImus was signiﬁcantly
lower in the exercise group compared to the control group (p< 0.05). Upper
arm muscle area (UAMA) and mid arm muscle circumference were signiﬁcantly
increased in the exercise group compared to the control group (p< 0.05 and p< 0.05
respectively). Pimax and Pemax were signiﬁcantly related to UAMA in the whole
cohort of CF patients. Pulmonary function was not signiﬁcantly different in the
exercise group compared to the control group. These results suggest that CF patients
that undertake regular aerobic exercise maintain higher indices of respiratory muscle
strength and lower PTImus values, while increased UAMA values in exercising
patients highlight the importance of muscular competence in respiratory muscle
function.
170 Quantifying physical activity in leisure time in adults with cystic
ﬁbrosis and association with disease severity: a preliminary
study
M. Ahmed1, M. O’Mahony1. 1University College Hospital Galway, Respiratory,
Galway, Ireland
Aim: Physical exercise has been shown to improve airway clearance and pulmonary
function in patient with cystic ﬁbrosis (PWCF). Quantifying exercise should be part
of the clinical evaluation. In this study we quantiﬁed physical exercise using a Rating
of Perceived Exertion (RPE) scale.
Methods: We conducted a telephone survey to enquire about the individuals
exercise patterns during the previous week and historically. We measured intensity
of physical activity using the RPE scale and recorded the duration and type of
activity. BMI, lung function and annual exacerbation rate were also recorded.
Results: 15 patients were interviewed. Mean age was 27.1 years (±5.65) with 8
(53.3%) males and 7 (46.7%) females. Mean FEV1% was 63% (±20%) and BMI
20.6 kg/m2 (±3.2). 12 patients (80%) regularly played sports in the past but only
6 (40%) continue to do so. All participants felt that physical exercise has beneﬁts
speciﬁc to cystic ﬁbrosis, mostly improving airway clearance. Commonest reasons
not to participate were respiratory symptoms and disinterest. Mean duration of
exercise was 158 minutes/week (±157) and mean RPE score was 13.7(±1.9) which
corresponds to moderate intensity exercise.
Conclusion: PWCF perceive the importance of physical exercise. Most formally
participated in sports in the past but more than half stop due to lack of motivation
or symptoms. Many patients though exercise for more than two hours per week
at moderate intensity, yet there is no scoring system commonly used in clinical
practice to evaluate the duration and intensity of exercise in CF. The RPE may ﬁt
that role but further validation in PWCF is necessary.
171 Physicochemical compatibility and stability of nebulizable drug
admixtures containing Dornase alfa and tobramycin
A. Klemmer1, I. Kraemer1, W. Kamin2. 1University Medical Center Mainz,
Pharmacy, Mainz, Germany; 2Lutherian Hospital Hamm, Pediatric Department,
Hamm, Germany
Objective: The objective of this in-vitro study was to determine whether ad-
mixtures of the inhalation solutions Pulmozyme® (Dornase alfa) and Bramitob®
(tobramycin) are physicochemically compatible. In addition the aerodynamic pa-
rameters of the admixtures were analyzed in comparison to the nebulization of the
unmixed solutions.
Methods: 2.5ml Pulmozyme® and 4.0ml Bramitob®were mixed and stored at
room temperature and under ambient light conditions over a period of 24 h.
Tobramycin concentrations were determined by using a ﬂuorescence immunoassay.
Stability of dornase alfa was determined by size-exclusion high performance liquid
chromatography, ultraviolet spectroscopy, sodium dodecyl sulphate polyacrylamide
gel electrophoresis and tentacle strong cation-exchange chromatography. In addition,
pH values and osmolality of the admixture were measured over the testing period
and test solutions were visually examined for any changes. Aerosols were generated
with the PARI eFlow® rapid and aerodynamic particle sizing was performed via
cascade impaction with the Next Generation Pharmaceutical Impactor
Results and Conclusion: The stability tests used, revealed that neither the
stability of tobramycin nor the stability of dornase alfa was affected by mixing
the two drug products. Aerosol characteristics of the admixture of Pulmozyme®
and Bramitob® were compared to those of admixtures with sodium chloride
solution 0.9%. No relevant changes in particle size distribution, Mass Medium
Aerodynamic Diameter, Geometric Standard Deviation and Fine Particle Fraction
were observed. Admixtures of Pulmozyme® and Bramitob® can be designated as
compatible for a limited period of time.
172 Nebulised aztreonam lysine (AZLI) use in patients with
non-immediate reactions to intravenous aztreonam
S.P. Conway1, P. Whitaker1, C. Etherington1, D. Peckham1, S. Wynne1. 1Leeds
Teaching Hospitals NHS Trust, Leeds, United Kingdom
Introduction: AZLI, because of its high cost, is often reserved for patients who
have exhausted other therapeutic options. In these patients, usually with advanced
lung disease, non-immediate hypersensitivity reactions to b-lactam antibiotics are
common. Up to 20% of patients have multiple b-lactam reactions [1]. At the Leeds
Adult Unit 10% have had a previous hypersensitivity reaction to IV aztreonam. The
aim of this study was to assess AZLI safety in these patients.
Patients and Methods: 4 patients intolerant of, or not clinically responding to,
alternative nebulised antibiotics, and with non-immediate reactions to IV aztreonam,
received AZLI tds, (predicted FEV1 17 to 34%). Patients had skin prick testing
to ensure no immediate reactivity. A full test dose of AZLI was given under
supervision.
Results: All were skin prick test negative. Test doses were uneventful with no
signiﬁcant fall in FEV1. Full dose AZLI was continued 1 month. No adverse
events were reported.
Discussion: Structurally there are no differences between the IV and nebulised
forms although the latter contains arginine rather than lysine. The study patients
were truly hypersensitive to IV aztreonam. 3 of the 4 had recently reacted again
on re-exposure. It is likely that the inhaled route is less immunogenic than the IV
route and the threshold is not reached in the peripheral circulation that triggers the
hypersensitivity reaction.
Conclusion: Patients with mild non-immediate reactions to IV aztreonam who
qualify for AZLI use should have a trial of treatment.
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